STRIDE - STimulating Immune Response In aDvanced brEast Cancer

Phase 3 Terminated 16 enrolled EMD Serono

RandomizedParallel-groupQuadruple-blindTreatment

Summary

EMD Serono has decided to permanently terminate the trial EMR 200038-010 (STRIDE) in the indication of breast cancer following the clinical hold on the investigational new drug application for tecemotide (L-BLP25).

Timeline

Start: 2009-09
Primary completion: 2010-08
Completion: 2010-08

Publications

Gorodetska I, Samusieva A, Lahuta T, Ponomarova O, Socha O, Kozeretska I. Exploring New Frontiers: Alternative Breast Cancer Treatments Through Glycocalyx Research. Breast J. 2025 May 22;2025:9952727. doi: 10.1155/tbj/9952727. eCollection 2025.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tecemotide	Vaccine	930 ug	Subcutaneous
Background	Cyclophosphamide	Other / unclassified	300 mg/m2	Intravenous

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

Summary

Timeline

Publications

Drugs

Indications